CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
罕见序列解读 CAR-T 细胞治疗结局
英文原题：Rare Sequences Make Sense of CAR T-cell Therapy Outcomes.
查看英文原题
Rare Sequences Make Sense of CAR T-cell Therapy Outcomes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本期中，Pulsipher及其同事在急性淋巴细胞白血病患者接受替沙仑赛治疗后，采用下一代测序检测白血病特异性序列。目前该领域的一项挑战，是尽早识别可能治疗失败的患者，以便规划后续治疗，例如干细胞移植。治疗第28天检测到低于该技术常规检测限的疾病（每百万个细胞中不足1个），与较差结局相关，因此可能用于识别可从辅助治疗中获益的患者。Pulsipher等人的相关论文见第66页。
展开英文摘要原文
In this issue, Pulsipher and colleagues used next-generation sequencing to detect leukemia-specific sequences following tisagenlecleucel therapy of acute lymphoblastic leukemia. A challenge for the field currently is to identify which patients will have therapy failure and to do so early enough to allow planning for further treatment, for example, stem cell transplantation.
Detection of disease below the standard detection level for this technique (less than one per million cells) at day 28 was associated with poorer outcomes and potentially therefore could be used to identify those that might benefit from adjunctive therapies. See related article by Pulsipher et al. , p. 66 .
论文信息
- 作者
- Ghorashian S、Bartram J
- 单位
- Department of Haematology Great Ormond Street Hospital for Children, London, United Kingdom. s.ghorashian@ucl.ac.uk.United Kingdom
- 文献类型
- 评论
- 期刊
- Blood cancer discovery2022 Jan
- 原文标识
- PubMed 35019857 · DOI 10.1158/2643-3230.BCD-21-0199
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →